MARC Record from Library of Congress

LEADER: 02913cam a22004577a 4500
001 2013414346
003 DLC
005 20140308082239.0
007 cr cn|||||||||
008 130620s2012 dcua b 100 0 eng c
010 $a 2013414346
016 7 $a101582836$2DNLM
016 7 $a016066521$2Uk
020 $a9780309219297 (pbk.)
020 $a0309219299 (pbk.)
035 $a(OCoLC)ocn767570602
040 $aNLM$beng$cNLM$dBTCTA$dUPM$dAAA$dNRZ$dYDXCP$dUKMGB$dCDX$dOCLCO$dDLC
042 $apcc
043 $an-us---
050 00 $aR853.C55$bP82 2011
060 00 $a2012 D-187
060 10 $aQV 771.4
082 00 $a610.72/4$223
111 2 $aPublic Engagement and Clinical Trials: New Models and Disruptive Technologies$d(2011 :$cMount Sinai School of Medicine)
245 10 $aPublic engagement and clinical trials :$bnew models and disruptive technologies : workshop summary /$cVictoria Weisfeld, Rebecca A. English, and Anne B. Claiborne, rapporteurs ; Forum on Drug Discovery, Development, and Translation, Board on Health Sciences Policy, Institute of Medicine of the National Academies.
260 $aWashington, D.C. :$bNational Academies Press,$cc2012.
300 $axvi, 124 p. :$b1 col. ill. ;$c23 cm.
504 $aIncludes bibliographical references (p. 85-87).
505 0 $aIntroduction -- Recruitment challenges in clinical trials for different diseases and conditions -- Models for public engagement -- Messages and methods for public engagement -- The media -- Novel clinical trials designs -- The health system's structure and culture -- Toward a patient-centered strategy for clinical trials.
520 $aClinical trials provide essential information needed to turn basic medical research findings into patient treatments. New treatments must be studied in large numbers of humans to find out whether they are effective and to assess any harm that may arise from treatment. There is growing recognition among many stakeholders that the U.S. clinical trials enterprise is unable to keep pace with the national demand for research results. The IOM, along with the Mount Sinai School of Medicine, held a workshop June 27-28, 2011, to engage stakeholders and experts in a discussion about possible solutions to improve public engagement in clinical trials.
530 $aAlso issued online.
650 0 $aClinical trials$zUnited States$vCongresses.
650 12 $aClinical Trials as Topic$zUnited States$vCongresses.
700 1 $aWeisfeld, Victoria D.
700 1 $aEnglish, Rebecca A.
700 1 $aClaiborne, Anne B.
710 2 $aInstitute of Medicine (U.S.).$bForum on Drug Discovery, Development, and Translation.
710 2 $aMount Sinai School of Medicine.
856 4 $uhttp://www.ncbi.nlm.nih.gov/books/NBK91498/
856 4 $uhttp://www.nap.edu/catalog.php?record%5Fid=13237
856 41 $3National Academies Press$uhttp://www.nap.edu/catalog.php?record_id=13237